In Wednesday’s Wall Street session, Organon & Co (NYSE:OGN) shares traded at $12.93, down -1.75% from the previous session.
OGN stock price is now -7.17% away from the 50-day moving average and -23.17% away from the 200-day moving average. The market capitalization of the company currently stands at $3.36B.
With the price target enhanced from $18 to $20, JP Morgan Downgraded its rating from Neutral to Underweight for Organon & Co (NYSE: OGN). On November 03, 2023, Goldman Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $33 to quote $16, while ‘Barclays’ rates the stock as ‘Overweight’
A total of 0.34% of the company’s stock is owned by insiders.
During the past 12 months, Organon & Co has had a low of $10.45 and a high of $23.10. As of last week, the company has a debt-to-equity ratio of 19.14, a current ratio of 1.60, and a quick ratio of 1.11. According to the stock market information, the enterprise value for the company is $11696295936, which is based on a 3.88 price-to-earnings ratio, a 38.79 price-to-earnings-growth ratio, and a beta of 0.70. The fifty day moving average price for OGN is $13.9294 and a two-hundred day moving average price translates $16.829 for the stock.
The latest earnings results from Organon & Co (NYSE: OGN) was released for 2024-12-31. The net profit margin was 13.49% and return on equity was 429.85% for OGN. The company reported revenue of $1.59 billion for the quarter, compared to $1.6 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -0.38 percent.
